Intellia Therapeutics, Inc. (NTLA) Income Statement
NTLA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNTLA revenue and net income
Where NTLA's revenue goes
2025Each bar shows an amount and its share of revenue. NTLA kept −609.9% of revenue as net income.
NTLA profit margins
NTLA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +16.9% | +9.1% | +3.1% | +27.3% |
| Gross profit | +8.7% | +5.1% | −2.3% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NTLA quarterly EPS vs estimates
Intellia Therapeutics beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.82).
NTLA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M |
| Cost of revenue | $15.9M | $10.3M | $9.0M | $7.6M | $6.9M | $150.4M | $108.4M | $89.1M | $67.6M | $31.8M |
| Gross profit | $51.7M | $47.6M | $27.3M | $44.5M | $33.1M | $58.0M | −$65.3M | $30.4M | $26.1M | $16.5M |
| Research & development | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M | $150.4M | $108.4M | $89.1M | $67.6M | $31.8M |
| Sales, general & admin | $119.8M | $125.8M | $116.5M | $90.3M | $71.1M | $44.2M | $41.1M | $32.2M | $28.0M | $16.8M |
| Total operating expenses | $492.7M | $581.9M | $542.6M | $502.7M | $300.9M | $194.6M | $41.1M | $121.3M | $95.7M | $48.6M |
| Operating income | −$441.0M | −$534.3M | −$515.3M | −$458.2M | −$267.9M | −$136.6M | −$106.4M | −$90.9M | −$69.6M | −$32.2M |
| Interest income | $29.2M | $47.8M | $49.8M | $8.5M | $1.3M | $2.4M | $6.8M | $5.5M | $2.0M | $525,000 |
| Interest expense | — | — | — | $8.5M | $6.9M | $2.4M | $0 | $0 | $0 | $0 |
| Income before taxes | −$412.7M | −$519.0M | −$481.2M | −$474.2M | −$267.9M | −$134.2M | −$99.5M | −$85.3M | −$67.5M | −$31.6M |
| Income taxes | — | — | −$49.7M | $16.0M | −$8.2M | −$8.7M | −$6.8M | $5.5M | −$3.0M | −$1.1M |
| Net income | −$412.7M | −$519.0M | −$481.2M | −$474.2M | −$259.7M | −$125.6M | −$99.5M | −$85.3M | −$67.5M | −$31.6M |
| EBITDA | −$396.8M | −$508.7M | −$472.2M | −$466.6M | −$261.0M | −$130.3M | −$100.8M | −$86.4M | −$66.6M | −$31.1M |
| EPS (diluted) | −$3.84 | −$5.25 | −$5.41 | −$6.18 | −$3.76 | −$2.40 | −$2.11 | −$1.99 | −$1.86 | −$10.61 |
| Gross margin | 76.5% | 82.2% | 75.3% | 85.5% | 100.0% | 100.0% | −151.5% | 100.0% | 100.0% | 100.0% |
| Operating margin | −651.7% | −923.1% | −1,420.5% | −879.0% | −810.4% | −235.5% | −246.8% | −298.6% | −266.3% | −195.2% |
| Net margin | −609.9% | −896.8% | −1,326.5% | −909.8% | −785.8% | −216.5% | −230.9% | −280.4% | −258.6% | −192.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $15.0M | $23.0M | $13.8M | $14.2M | $16.6M | $12.9M | $9.1M | $7.0M | $28.9M | $0 | $12.0M |
| Cost of revenue | $0 | $2.2M | $6.0M | $78.9M | $80.5M | $0 | $116.9M | $109.2M | $2.6M | $2.5M | $2.5M | $2.3M |
| Gross profit | $7.7M | $12.8M | $17.0M | −$65.2M | −$66.3M | $16.6M | −$104.0M | −$100.1M | $4.4M | $26.4M | −$4.4M | $9.7M |
| Research & development | $82.6M | $80.7M | $88.7M | $94.7M | $97.0M | $108.4M | $116.9M | $123.4M | $111.6M | $109.3M | $109.0M | $113.7M |
| Sales, general & admin | $37.8M | $34.8M | $33.1M | $30.5M | $27.2M | $29.0M | $32.4M | $30.5M | $31.8M | $31.1M | $29.0M | $29.4M |
| Total operating expenses | $120.4M | $113.4M | $115.7M | $46.3M | $43.7M | $137.4M | $32.4M | $44.7M | $143.4M | $140.4M | $135.5M | $140.8M |
| Operating income | −$112.8M | −$100.5M | −$98.7M | −$111.5M | −$110.0M | −$120.8M | −$136.4M | −$144.8M | −$139.0M | −$114.0M | −$139.9M | −$131.1M |
| Interest income | $5.8M | $5.2M | $6.5M | $6.7M | $7.4M | $8.6M | $10.6M | $12.1M | $12.4M | $12.6M | $12.5M | $12.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $8.8M | — |
| Income before taxes | −$106.6M | −$96.2M | −$95.8M | −$101.3M | −$101.3M | −$114.3M | −$128.9M | −$135.7M | −$147.0M | −$107.4M | −$132.2M | −$122.2M |
| Income taxes | — | — | — | — | — | — | — | — | — | $2.5M | $40.6M | −$15.0M |
| Net income | −$106.6M | −$96.2M | −$95.8M | −$101.3M | −$101.3M | −$114.3M | −$128.9M | −$135.7M | −$147.0M | −$107.4M | −$132.2M | −$122.2M |
| EBITDA | −$104.6M | −$94.0M | −$95.4M | −$96.4M | −$98.8M | −$111.8M | −$126.3M | −$133.1M | −$144.4M | −$104.9M | −$129.7M | −$119.9M |
| EPS (diluted) | −$0.80 | −$0.81 | −$0.83 | −$0.92 | −$0.99 | −$1.10 | −$1.27 | −$1.34 | −$1.52 | −$1.12 | −$1.46 | −$1.38 |
| Gross margin | 100.0% | 85.4% | 73.9% | −472.8% | −465.3% | 100.0% | −807.9% | −1,098.3% | 62.6% | 91.3% | — | 80.9% |
| Operating margin | −1,472.3% | −668.1% | −428.9% | −808.9% | −772.2% | −726.6% | −1,059.9% | −1,589.0% | −1,998.6% | −394.0% | — | −1,093.3% |
| Net margin | −1,392.3% | −639.5% | −416.2% | −735.2% | −710.8% | −687.6% | −1,001.2% | −1,489.5% | −2,112.6% | −371.3% | — | −1,019.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NTLA's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NTLA financial results
In fiscal year 2025 (ended December 31, 2025), Intellia Therapeutics reported revenue of $67.7 million, up 16.9% from the year before. It had a net loss of $412.7 million, a net profit margin of −609.9%. Diluted earnings per share came to −$3.84. Over five years revenue grew at an average rate of 3.1% a year.
See the NTLA stock overview for the latest quote and news, or the NTLA chart for price history and technical indicators.
NTLA income statement FAQ
What is Intellia Therapeutics's annual revenue?
Intellia Therapeutics reported total revenue of $67.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 16.9% from $57.9 million the previous year.
Is Intellia Therapeutics profitable?
No. Intellia Therapeutics reported a net loss of $412.7 million in fiscal 2025, a net profit margin of −609.9%; its operating margin was −651.7%.
What is Intellia Therapeutics's gross margin?
Intellia Therapeutics's gross margin was 76.5% in fiscal 2025: for every $100 of revenue, Intellia Therapeutics kept $76 after the direct cost of its products and services.
How much does Intellia Therapeutics spend on research and development?
Intellia Therapeutics spent $388.9 million on research and development in fiscal 2025, 574.6% of revenue.
How fast is Intellia Therapeutics growing?
Revenue grew 3.1% a year on average over the last five fiscal years, from $58.0 million to $67.7 million.
What are Intellia Therapeutics's earnings per share?
Intellia Therapeutics earned $-3.84 per diluted share in fiscal 2025, compared with $-5.25 a year earlier.
When will Intellia Therapeutics report its next earnings?
Intellia Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Intellia Therapeutics's fiscal year end?
Intellia Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.